Fig. 5: Impact of cytoreductive therapy on thrombosis in those with QRISK3 score ≽7.5%.
From: QRISK3 score is predictive of thrombotic risk in patients with myeloproliferative neoplasms
A, B Differences in risk of thrombosis for essential thrombocythemia (ET) and polycythemia vera (PV) patients with QRISK3 ≥ 7.5 between those receiving cytoreductive treatment and those who were not.
